RZLT
Rezolute, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +3 | 50.24M | $261.09M | +9 | −6 |
| Q1 2026 | 63 | +7 | 53.20M | $162.23M | +14 | −7 |
| Q4 2025 | 56 | +1 | 61.70M | $145.62M | +3 | −2 |
| Q3 2025 | 14 | +1 | 31.48M | $295.95M | +2 | −1 |
| Q2 2025 | 10 | 0 | 26.66M | $118.90M | +2 | −2 |
| Q1 2025 | 7 | -1 | 3.87M | $11.23M | — | −1 |
| Q4 2024 | 8 | 0 | 4.74M | $23.24M | — | — |
| Q3 2024 | 7 | +1 | 2.88M | $13.99M | +1 | — |
| Q2 2024 | 6 | — | 2.25M | $9.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 1.05M | — | $4.50M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Marshall Wace ✦ | 1.05M | — | $4.50M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 353.70K | — | $1.52M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 353.70K | — | $1.52M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 337.53K | — | $1.45M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 315.85K | — | $1.36M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 180.42K | — | $775,810 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 17.65K | — | $75,899 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 81.00K shares, $247 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.